Regulatory News
Monday, December 19, 2016
UPDATE 3-Clovis's ovarian cancer drug wins accelerated FDA approval
* Shares soar as much as 26 pct
(Adds Lynparza sales and Rubraca sales estimate)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment